| 01 Apr 2009 |
|
Obs-Gyne Exhibition & Congress Speakers Tackle Cervical Cancer Vaccine Issues And Encourage Advocacy
- Text size
Dubai: 01 April, 2009 - Discussions on the management of cervical cancer as well as the efficacy of therapeutic cervical cancer vaccines were the key highlights of the first day of the Arab Health Obs-Gyne Exhibition and Congress 2009 that opened on 1 April in Abu Dhabi.
National and international obstetricians and gynecologists are participating at the event that runs until 03 April at the Abu Dhabi National Exhibition Center.
The conference also marks the first time Professor Suzanne Garland, a leading clinical microbiologist in Australia, presented in the UAE. Professor Garland is well known for her research on infectious diseases, having been involved in clinical trials of antivirals and vaccines globally.
Perhaps one of the most important prevention topics discussed during the conference was presented by Professor Garland regarding the quadrivalent cervical cancer vaccine.
Professor Suzanne Garland said: "Cervical cancer can affect anyone, probably with very tragic consequences. Worldwide, every two minutes a woman dies of cervical cancer! The lack of awareness regarding this disease shows how little the public is informed. Many people present for the first time with late stage disease whereas vaccines are now available and provide a means to preventing cervical cancer."
Consistently, worldwide 70% cervical cancer is caused by strains 16 and 18 of the human papilloma virus (HPV). There are vaccines that target this virus and can prevent cervical cancer in women. In addition, the quadrivalent vaccine is protective against 90% of genital warts, most of which are caused by strains 6 and 11 of the virus. These are difficult to treat, are common, and cause high psychosocial burden. Indeed, the UAE Ministry of Health is studying the need and feasibility of introducing a National Cervical Cancer Screening program.
The main goal of the presentations today was to educate healthcare professionals and provide them with the tools and information they need to become advocates for cervical cancer prevention within their own communities.
-Ends-
About Professor Suzanne Garland:
Director of Microbiological Research and Head of Clinical Microbiology and Infectious Diseases.
Royal Womens Hospital, Senior Consultant Microbiology, Royal Childrens Hospital Professor.
Faculty of Medicine, Dentistry and Health Department of Obstetrics and Gynaecology University of Melbourne.
Suzanne Garland is Director of Microbiological Research and Head of Clinical Microbiology and Infectious Diseases, Royal Women's Hospital, Senior Consultant Microbiology and Infectious Diseases, Royal Women's and Royal Children's Hospitals, and Professor, Department of Obstetrics & Gynaecology, University of Melbourne. She is also a practicing Sexual Health Physician.
As one of Victoria's leading Clinical Microbiologists, particularly in women's health, Professor Garland is well known for her research on infectious diseases, having been involved in clinical trials of antivirals and vaccines for herpes simplex virus. She has a special interest in the management of herpes in the pregnant woman and the neonate. She is an advisor to World Health Organisation in the area of sexually transmitted infection diagnosis and the prophylactic HPV vaccine.
Agency:
Dr Sabah Al-Lawati
Senior Account Manager
Jiwin Public Relations
A member of Media Services Group
Phone: +971-4-3755880
Email: Sabah.AlLawati@jiwin.ae
Ghaith Nazzal
Senior Account Executive
Jiwin Public Relations
A member of Media Services Group
Phone: +971-4-3692926
Email: Ghaith.Nazzal@Jiwin.ae
© Press Release 2009
Zawya is a distributor (and not a publisher) of content supplied by third parties and subscribers. Any opinions, advice, statements, services, offers, or other information or content expressed or made available by those third parties, including information providers, subscribers or other users of the Service, are those of the respective author(s) or distributor(s) and not of the Company. The Company neither endorses nor is responsible for the accuracy or reliability of any opinion, advice or statement made on the Service by anyone other than authorized Service employee spokespersons while acting in their official capacities. The Company is not responsible for any infringement of intellectual property rights or breach of any applicable law or regulation, including regulation in relation to financial services or the distribution of financial products, defamation, data protection, telecommunications (including regulations relating to excessive use, spamming or other abusive activities) or obscene, offensive or illegal content). Under no circumstances will the Company be liable for any loss or damage caused by a member's reliance on information obtained through the Service. It is the responsibility of member to evaluate the accuracy, completeness or usefulness of any information, opinion, advice or other content available through the Service. Please seek the advice of professionals, as appropriate, regarding the evaluation of any specific information, opinion, advice or other content.
Read the full Member Agreement
http://www.zawya.com/legal/NewsLetter.cfm?name=disclaimer
Post a Comment
1.1 Contain any material which is libelous or defamatory of any person, is obscene, offensive, hateful or inflammatory or causes damage to the reputation of any person or organisation.
1.2 Promote sexually explicit material, violence, discrimination based on race, sex, religion, nationality, disability, sexual orientation or age or any illegal activity.
1.3 Be made in breach of any legal duty owed to a third party, such as a contractual duty or a duty of confidence.
1.4 Be threatening, abuse or invade another's privacy, or cause annoyance, inconvenience or needless anxiety.
1.5 Be used to impersonate any person, to misrepresent your identity or affiliation with any person, or be likely to deceive any person.
1.6 Give the impression that they represent Zawya.
1.7 Advocate, promote or assist any unlawful act such as (by way of example only) copyright infringement or computer misuse.